What is Niagen Bioscience Inc. Annual Revenue?

Niagen Bioscience Inc. Annual Revenue rose 19.18%, in the last year to $99.6 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

What is Niagen Bioscience Inc. Annual Net Profit?

Niagen Bioscience Inc. Annual Net Profit rose 273.15% in the last year to $8.55 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

What is Niagen Bioscience Inc. Price to Earning Ratio?

Niagen Bioscience Inc. Price to Earning Ratio is 70.47, higher than its sector PE ratio of 4.23.

What is Niagen Bioscience Inc. Stock Price?

Niagen Bioscience Inc. Stock Price rose 117.7% and outperformed its sector by 108.63% in the past year.

What is Niagen Bioscience Inc. Quarterly Revenue?

Niagen Bioscience Inc. Quarterly Revenue rose 37.41% YoY to $29.12 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

What is Niagen Bioscience Inc. Quarterly Net profit?

Niagen Bioscience Inc. Quarterly Net profit rose 6,197.37% YoY to $7.18 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

What is Niagen Bioscience Inc. Mutual Fund Holding?

Niagen Bioscience Inc. Mutual Fund Holding decreased by 0.1% in the last quarter to 22.48.

What is Niagen Bioscience Inc. Promoter Share Holding?

Niagen Bioscience Inc. Promoter Share Holding increased by 0% in the most recent quarter to 9.46%.

What is Niagen Bioscience Inc. Institutional Holding?

Niagen Bioscience Inc. Institutional Holding remained the same in the last quarter at 29.09%.

How is the Niagen Bioscience Inc. today?

The Niagen Bioscience Inc. today is trading in the green, up by 1.44% at 7.75.

How has Niagen Bioscience Inc. performed historically?

The Niagen Bioscience Inc. is currently trading up 1.44% on an intraday basis in the past week the index fell -1.15%. The index has been up 41.17% in the past quarter and rose 117.70% in the past year. You can view this in the overview section.

Niagen Bioscience Inc. XNAS: NAGE

Niagen Bioscience Inc. Live Share Price Today, Share Analysis and Chart

Name: Niagen Bioscience Inc.: Is Infosys Ltd. worth buying?
Item: Niagen Bioscience Inc.
Rating: 2.318652625
Author: Trendlyne DVM scores

Expensive Rocket

Download real time

7.75 0.11 (1.44%)

236.96% Gain from 52W Low

681.5K XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Niagen Bioscience Inc. Key Metrics

My Metrics

Default

Market Capitalization High in industry Unavailable in chosen country	602.6
PE TTM High in industry Unavailable in chosen country	70.5
PEG TTM High in industry Unavailable in chosen country	0.3
Price to Book High in industry Unavailable in chosen country	17.4
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	29.1
Revenue Growth Qtr YoY % Market Runner Up Unavailable in chosen country	37.4
Operating Revenue growth TTM % Below industry Median Unavailable in chosen country	19.2
Net Profit Qtr Growth YoY % Market Leader Unavailable in chosen country	6,197.4
Net Profit TTM Growth % High in industry Unavailable in chosen country	273.1
Operating Profit Margin TTM % Below industry Median Unavailable in chosen country	7.8
Piotroski Score Below industry Median Unavailable in chosen country	4
Rel Perf vs Sector quarter% Unavailable in chosen country	32.5

All financials are in USD Million and price data in USD

Medium Financial Strength

44.4 / 100

Expensive Valuation

19.3 / 100

Technically Bullish

77.3 / 100

Expensive Rocket These stocks are a favourite among investors due to their bullish nature, good technical aspects but they have bad valuation and medium financials. View Similar Embed DVM

1Yr Price target upside is 14%

5 analysts

Check Before You Buy

Check P/E Buy Sell Zone

Strong Buy Zone

8.0 % into P/E buy sell zone

Strong upside potential

% time spent below current P/E

Gains already realized

Niagen Bioscience Inc. Stock Price Analysis

Day Price Range 1.4% 1 Day return Unavailable in chosen country	7.8 (LTP) 7.57.8 LowHigh
Week Price Range -1.2% 1 Week return Unavailable in chosen country	7.8 (LTP) 7.48 LowHigh
Month Price Range 43.0% 1 Month return Unavailable in chosen country	7.8 (LTP) 5.29.2 LowHigh
52 Week Price Range 117.7% 1 Year return Unavailable in chosen country	7.8 (LTP) 2.39.2 LowHigh

View full Share Price History

Niagen Bioscience Inc. Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Niagen Bioscience Inc.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

0.1

Avg. Estimate

0.1

Low Estimate

0.1

High Estimate

0.2

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 18.2% in FY25

Consensus Recommendation

5 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 5 analysts for Niagen Bioscience Inc. is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Niagen Bioscience Inc. Stock Analysis

Niagen Bioscience Inc. stock analysis with key metrics, changes, and trends.

Niagen Bioscience Inc. Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$99.6 M	19.18%	positive	Annual Revenue rose 19.18%, in the last year to $99.6 M. Its sector's average revenue growth for the last fiscal year was 7.46%.
Annual Net Profit	$8.55 M	273.15%	positive	Annual Net Profit rose 273.15% in the last year to $8.55 M. Its sector's average net profit growth for the last fiscal year was -32.43%.
Price to Earning Ratio	70.47	-	negative	Price to Earning Ratio is 70.47, higher than its sector PE ratio of 4.23.
Stock Price	$7.75	117.7%	positive	Stock Price rose 117.7% and outperformed its sector by 108.63% in the past year.
Quarterly Revenue	$29.12 M	37.41%	positive	Quarterly Revenue rose 37.41% YoY to $29.12 M. Its sector's average revenue growth YoY for the quarter was 5.96%.
Quarterly Net profit	$7.18 M	6197.37%	positive	Quarterly Net profit rose 6,197.37% YoY to $7.18 M. Its sector's average net profit growth YoY for the quarter was -47.3%.
Mutual Fund Holding	22.48 %	-0.1%	negative	Mutual Fund Holding decreased by 0.1% in the last quarter to 22.48.
Promoter Share Holding	9.46 %	0%	positive	Promoter Share Holding increased by 0% in the most recent quarter to 9.46%.
Institutional Holding	29.09 %	0%	neutral	Institutional Holding remained the same in the last quarter at 29.09%.

VIEW LESS

Loading data..

Niagen Bioscience Inc. - Company Profile

What does Niagen Bioscience Inc. do?

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Gross Remuneration

2024

Gross Remuneration

Year

Niagen Bioscience Inc. Live Share Price Today, Share Analysis and Chart

236.96% Gain from 52W Low

Niagen Bioscience Inc. Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Niagen Bioscience Inc. Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Niagen Bioscience Inc. Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Niagen Bioscience Inc.'s Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

EPS is expected to grow by 18.2% in FY25

Consensus Recommendation

The consensus recommendation from 5 analysts for Niagen Bioscience Inc. is STRONG BUY

Niagen Bioscience Inc. Stock Analysis

Niagen Bioscience Inc. stock analysis with key metrics, changes, and trends.

Annual Revenue rose 19.18%, in the last year to $99.6 M. Its sector's average revenue growth for the last fiscal year was 7.46%.

Annual Net Profit rose 273.15% in the last year to $8.55 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio is 70.47, higher than its sector PE ratio of 4.23.

Stock Price rose 117.7% and outperformed its sector by 108.63% in the past year.

Quarterly Revenue rose 37.41% YoY to $29.12 M. Its sector's average revenue growth YoY for the quarter was 5.96%.

Quarterly Net profit rose 6,197.37% YoY to $7.18 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Mutual Fund Holding decreased by 0.1% in the last quarter to 22.48.

Promoter Share Holding increased by 0% in the most recent quarter to 9.46%.

Institutional Holding remained the same in the last quarter at 29.09%.

Niagen Bioscience Inc. - Company Profile

What does Niagen Bioscience Inc. do?

Niagen Bioscience Inc. Management structure

Ms. Brianna Gerber

Chief Financial Officer and Principal Accounting Officer

Mr. Jeong James Lee

Controller

Mr. Ozan Pamir

Chief Financial Officer and Principal Accounting Officer

Mr. Robert N. Fried

Chief Executive Officer and Director

Niagen Bioscience Inc. Board of directors

Mr. Robert N. Fried

Chief Executive Officer and Director

Mr. Steven D. Rubin

Lead Independent Director

Mr. Frank L. Jaksch, Jr

Chairman of the Board

Mr. Hamed Shahbazi

Independent Director

Ms. Wendy Yu

Independent Director

Ms. Kristin Patrick

Independent Director

Niagen Bioscience Inc. FAQ

How is Niagen Bioscience Inc. today?